Mutual of America Capital Management LLC reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 37.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 67,048 shares of the company’s stock after selling 40,326 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Neurocrine Biosciences were worth $8,244,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of NBIX. Victory Capital Management Inc. lifted its holdings in shares of Neurocrine Biosciences by 60.5% in the 3rd quarter. Victory Capital Management Inc. now owns 605,135 shares of the company’s stock valued at $74,402,000 after buying an additional 228,163 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Neurocrine Biosciences by 192.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 249,900 shares of the company’s stock valued at $30,725,000 after buying an additional 164,306 shares during the period. Standard Life Aberdeen plc acquired a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $16,815,000. Mainstay Capital Management LLC ADV lifted its holdings in shares of Neurocrine Biosciences by 3,156.2% in the 2nd quarter. Mainstay Capital Management LLC ADV now owns 134,970 shares of the company’s stock valued at $1,624,000 after buying an additional 130,825 shares during the period. Finally, Candriam Luxembourg S.C.A. lifted its holdings in shares of Neurocrine Biosciences by 87.4% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 150,069 shares of the company’s stock valued at $18,451,000 after buying an additional 69,969 shares during the period. 96.88% of the stock is owned by institutional investors and hedge funds.

NASDAQ NBIX opened at $86.24 on Wednesday. Neurocrine Biosciences, Inc. has a 1-year low of $68.22 and a 1-year high of $126.98. The company has a market capitalization of $8.00 billion, a P/E ratio of -53.23, a PEG ratio of 23.03 and a beta of 0.90.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Monday, November 5th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.04. Neurocrine Biosciences had a return on equity of 2.54% and a net margin of 2.40%. The firm had revenue of $151.80 million during the quarter, compared to the consensus estimate of $151.51 million. During the same period last year, the business posted ($0.13) EPS. Neurocrine Biosciences’s quarterly revenue was up 149.7% on a year-over-year basis. As a group, equities analysts predict that Neurocrine Biosciences, Inc. will post 0.19 earnings per share for the current fiscal year.

Several research firms have recently commented on NBIX. Stifel Nicolaus raised their price target on Neurocrine Biosciences from $137.00 to $142.00 and gave the company a “buy” rating in a report on Thursday, September 20th. Oppenheimer set a $140.00 price target on Neurocrine Biosciences and gave the company a “buy” rating in a report on Tuesday, September 4th. Leerink Swann assumed coverage on Neurocrine Biosciences in a research note on Monday, November 12th. They issued a “market perform” rating and a $110.00 price objective for the company. Piper Jaffray Companies set a $111.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Tuesday, November 6th. Finally, Cantor Fitzgerald set a $150.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Thursday, September 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seventeen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $124.88.

In other Neurocrine Biosciences news, Director Richard F. Pops sold 4,124 shares of the firm’s stock in a transaction on Monday, November 26th. The stock was sold at an average price of $91.37, for a total transaction of $376,809.88. Following the completion of the transaction, the director now owns 29,512 shares of the company’s stock, valued at $2,696,511.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gary A. Lyons sold 15,000 shares of the firm’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $114.41, for a total value of $1,716,150.00. The disclosure for this sale can be found here. Insiders have sold 37,747 shares of company stock valued at $4,098,171 in the last three months. 4.30% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Neurocrine Biosciences, Inc. (NBIX) Stake Lowered by Mutual of America Capital Management LLC” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.watchlistnews.com/neurocrine-biosciences-inc-nbix-stake-lowered-by-mutual-of-america-capital-management-llc/2662424.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Recommended Story: Risk Tolerance and Your Investment Decisions

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.